These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8855869)

  • 1. Case-control study of venous thromboembolism risk in users of hormone replacement therapy.
    Daly E; Vessey MP; Painter R; Hawkins MM
    Lancet; 1996 Oct; 348(9033):1027. PubMed ID: 8855869
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of venous thromboembolism in users of hormone replacement therapy.
    Daly E; Vessey MP; Hawkins MM; Carson JL; Gough P; Marsh S
    Lancet; 1996 Oct; 348(9033):977-80. PubMed ID: 8855852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study.
    Canonico M; Olié V; Carcaillon L; Tubert-Bitter P; Scarabin PY;
    Thromb Haemost; 2008 Jan; 99(1):246-8. PubMed ID: 18217166
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of venous thrombosis with hormone-replacement therapy.
    Vandenbroucke JP; Helmerhorst FM
    Lancet; 1996 Oct; 348(9033):972. PubMed ID: 8855846
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.
    Jick H; Derby LE; Myers MW; Vasilakis C; Newton KM
    Lancet; 1996 Oct; 348(9033):981-3. PubMed ID: 8855853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of exogenous hormones and risk of pulmonary embolism in women.
    Grodstein F; Stampfer MJ; Goldhaber SZ; Manson JE; Colditz GA; Speizer FE; Willett WC; Hennekens CH
    Lancet; 1996 Oct; 348(9033):983-7. PubMed ID: 8855854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estrogens and cardiovascular diseases: should current guidelines be changed?].
    Beller F; Theiss W
    Zentralbl Gynakol; 1994; 116(8):441-8. PubMed ID: 7941812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of parity, oral contraceptive use and hormone replacement therapy on the incidence of varicose veins.
    Jukkola TM; Mäkivaara LA; Luukkaala T; Hakama M; Laurikka J
    J Obstet Gynaecol; 2006 Jul; 26(5):448-51. PubMed ID: 16846875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Estrogen therapy and venous thromboembolic disease].
    Lévesque H; Courtois H
    Rev Med Interne; 1997; 18 Suppl 6():620s-625s. PubMed ID: 9515142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABC of arterial and venous disease. Varicose veins.
    London NJ; Nash R
    BMJ; 2000 May; 320(7246):1391-4. PubMed ID: 10818035
    [No Abstract]   [Full Text] [Related]  

  • 11. [Results of an enquiry into synthetic estroprogestatives and their effects on veins].
    van der Molen HR; Baute J
    Phlebologie; 1972; 25(3):237-42. PubMed ID: 4662047
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
    Bouligand J; Cabaret O; Canonico M; Verstuyft C; Dubert L; Becquemont L; Guiochon-Mantel A; Scarabin PY;
    Clin Pharmacol Ther; 2011 Jan; 89(1):60-4. PubMed ID: 21107315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk of venous thromboembolism during postmenopausal hormone therapy].
    Pedersen AT; Ottesen B
    Ugeskr Laeger; 1996 Nov; 158(48):6923-4. PubMed ID: 8984757
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of venous thrombosis with hormone replacement therapy.
    Scarabin PY
    Lancet; 1996 Dec; 348(9042):1668. PubMed ID: 8962022
    [No Abstract]   [Full Text] [Related]  

  • 15. [The outcome of an enquiry into synthetic estroprogestatives and their effects on venous circulation].
    Wallois P; Abeille JP; Griton P
    Phlebologie; 1972; 25(3):227-35. PubMed ID: 4662046
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
    Scarabin PY; Oger E; Plu-Bureau G;
    Lancet; 2003 Aug; 362(9382):428-32. PubMed ID: 12927428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
    Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A;
    Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for chronic ulceration in patients with varicose veins: a case control study.
    Robertson L; Lee AJ; Gallagher K; Carmichael SJ; Evans CJ; McKinstry BH; Fraser SC; Allan PL; Weller D; Ruckley CV; Fowkes FG
    J Vasc Surg; 2009 Jun; 49(6):1490-8. PubMed ID: 19497512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Puerperal thromboembolism.
    Fegan G; Henry M
    Br Med J; 1969 Feb; 1(5642):508-9. PubMed ID: 5764266
    [No Abstract]   [Full Text] [Related]  

  • 20. [Risk of venous thrombosis during postmenopausal estrogen therapy? The reporting system of adverse effects is functioning].
    Buajordet I; Dybwad TB
    Tidsskr Nor Laegeforen; 1997 Aug; 117(18):2644-5. PubMed ID: 9324824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.